Oxaliplatin is the most commonly used drug to treat colorectal cancer (CRC), but patients often develop resistance to it. So, researchers conducted a study to determine the effect of CBD in overcoming oxaliplatin resistance in CRC cells. They found that elevated NOS3 phosphorylation is an essential part of the development of oxaliplatin resistance, and CBD successfully decreased NOS3 phosphorylation. This effect resulted in cells overcoming oxaliplatin resistance, which suggests that CBD could be a new strategy to treat colorectal cancer.
Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.
A Kaempferol-3-O-β-D-glucoside, Intervention Effect of Astragalin on Estradiol Metabolism
A recent study found that a flavonoid known as astragalin possesses a strong anti-tumor effect. High levels of a metabolite formed from the hormone estradiol have been found in tumor tissues leading researchers to search for an inhibitor to prevent estradiol from forming the metabolite. This study has found that astragalin, which is a naturally occurring substance found in a variety of plants and wine, has an effective antitumor mechanism that inhibits the formation of the metabolite.
Effect of citrus peel extracts on the cellular quiescence of prostate cancer cells
A recent study has revealed that citrus peel extracts (CPE) have the potential to prevent prostate cancer from recurring in post-therapy cancer patients. A component of CPE, flavonoids, have previously been found to have anticancer effects, but appear to lack the correct structure to prevent tumors in patients with prostate cancer. This specific study found that the citric acid present in CPE was the contributing factor to its anticancer effects but mentioned that flavonoids should continue to be researched for chemopreventive benefits.
Additional research may show potential for CBD as a therapeutic agent for hepatocellular carcinoma
Cannabinoid (CBD) may be an effective treatment for hepatocellular carcinoma (HCC). Cannabinoid receptor 2 (CB2 receptor) has demonstrated anti-tumor behavior in other tumor types. In a new study, HCC cells treated with MDA19, a molecule that binds to the CB2 receptor, grew more slowly than untreated cells. With CBD also binding to the CB2 receptor, there may be precedent for research on the potential of CBD as a treatment for HCC.